Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume – Should You Buy?

Elekta AB (OTCMKTS:EKTAY) shares saw unusually-strong trading volume on Tuesday . Approximately 8,635 shares changed hands during trading, an increase of 250% from the previous session’s volume of 2,464 shares.The stock last traded at $5.0410 and had previously closed at $5.00.

Analysts Set New Price Targets

Separately, Zacks Research downgraded shares of Elekta from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Elekta Price Performance

The stock has a market cap of $1.86 billion, a PE ratio of -31.51 and a beta of 1.00. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The company’s fifty day moving average is $5.76 and its 200 day moving average is $6.02.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. The company had revenue of $521.00 million during the quarter. As a group, sell-side analysts anticipate that Elekta AB will post 0.43 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.